LNAI Short Volume
Lunai Bioworks Inc. (LNAI) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $5.3M, listed on NASDAQ, employing roughly 29 people, carrying a beta of 0.33 to the broader market. A company rebranding from Renovaro, focusing on AI-powered therapeutics and biodefense, with “Neurotoxicity Intelligence Technology” in development. Led by David H. Weinstein, public since 2025-09-30.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-05-15
- Short Volume
- 191.9K
- Total Volume
- 385.5K
- Short %
- 49.79%
- 30-Day Avg Short %
- 46.75%
Showing 30 days of FINRA short volume data for Lunai Bioworks Inc..
Learn how short volume is reported and how to read the data →
Frequently asked LNAI short volume questions
- What is the daily LNAI short volume?
- As of May 15, 2026, Lunai Bioworks Inc. (LNAI) short volume is 191.9K shares against 385.5K total reported volume, or 49.79% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is LNAI short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does LNAI short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.